|123.78||-0.9600||-0.77%||Vol 6.23M||1Y Perf 36.12%|
|Jun 11th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||137.55||Analyst Rating||Moderate Buy 1.57|
|Potential %||11.12||Finscreener Ranking||★+ 45.59|
|Insiders Trans % 3/6/12 mo.||-100/-100/-88||Value Ranking||★★+ 48.32|
|Insiders Value % 3/6/12 mo.||-100/-100/-92||Growth Ranking||★★★ 54.01|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-92||Income Ranking||★★★ 47.23|
|Market Cap||166.86B||Earnings Rating||Buy|
|Price Range Ratio 52W %||80.91||Earnings Date||27th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.42|
|EPS Growth Next 5 Years %||8.90|
|Avg. Weekly Volume||4.90M|
|Avg. Monthly Volume||4.85M|
|Avg. Quarterly Volume||4.74M|
Medtronic plc. (NYSE: MDT) stock closed at 123.78 per share at the end of the most recent trading day (a -0.77% change compared to the prior day closing price) with a volume of 6.25M shares and market capitalization of 166.86B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 90000 people. Medtronic plc. CEO is Geoffrey S. Martha.
The one-year performance of Medtronic plc. stock is 36.12%, while year-to-date (YTD) performance is 5.67%. MDT stock has a five-year performance of 45.15%. Its 52-week range is between 87.68 and 132.3, which gives MDT stock a 52-week price range ratio of 80.91%
Medtronic plc. currently has a PE ratio of 46.60, a price-to-book (PB) ratio of 3.24, a price-to-sale (PS) ratio of 5.54, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of 3.74%, a ROC of 4.37% and a ROE of 6.73%. The company’s profit margin is 11.98%, its EBITDA margin is 22.10%, and its revenue ttm is $30.12 Billion , which makes it $22.39 revenue per share.
Of the last four earnings reports from Medtronic plc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.42 for the next earnings report. Medtronic plc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Medtronic plc. is Moderate Buy (1.57), with a target price of $137.55, which is +11.12% compared to the current price. The earnings rating for Medtronic plc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Medtronic plc. has a dividend yield of 2.03% with a dividend per share of $2.52 and a payout ratio of 107.00%.
Medtronic plc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.51, ATR14 : 2.06, CCI20 : -65.48, Chaikin Money Flow : -0.24, MACD : -0.62, Money Flow Index : 40.32, ROC : -3.60, RSI : 45.33, STOCH (14,3) : 37.70, STOCH RSI : 0.74, UO : 44.29, Williams %R : -62.30), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Medtronic plc. in the last 12-months were: Bradley E. Lerman (Option Excercise at a value of $2 600 082), Bradley E. Lerman (Sold 44 034 shares of value $4 923 062 ), Carol A. Surface (Sold 15 000 shares of value $1 723 500 ), Geoffrey S. Martha (Option Excercise at a value of $614 925), Geoffrey S. Martha (Sold 11 712 shares of value $1 391 736 ), Karen L. Parkhill (Sold 2 004 shares of value $227 547 ), Omar Ishrak (Sold 763 shares of value $82 709 ), Richard H. Anderson (Buy at a value of $499 952), Robert J. White (Sold 10 930 shares of value $1 261 977 ), Robert Ten Hoedt (Option Excercise at a value of $250 020), Robert Ten Hoedt (Sold 26 315 shares of value $2 850 268 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.